Stock Ratings / Health Care / SLBT / financials

AURA (31) CADL (34) DBVT (23) IAM (49) ⌘ Pro Terminal →

SL Science Holding Limited (SLBT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: How profitable is SL Science Holding Limited (SLBT)?

In FY 2025 (10-K), SLBT converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $18.4M in free cash flow (0.5% FCF margin).

$1.20 +2.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.20

SL Science Holding Limited (SLBT) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $656.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SLBT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, SL Science Holding Limited (NASDAQ: SLBT) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $1.20 (+2.56% 1D, market cap $656.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SLBT ranks #407 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SLBT compare to AURA and CADL in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SLBT carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, AURA (Aura Biosciences Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and CADL (Candel Therapeutics Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $661.9M). Among the 5-stock peer group, SLBT leads on earnings multiple (N/A) while AURA leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SLBT?

▼

Per SLBT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002070534), SL Science Holding Limited generated $0 in revenue, $0 in net income, and $0 in free cash flow against $11.8K in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.20 (+0.27%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SLBT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY SLBT SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($18.4M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$1.51+1.3% Next Q

Q2 (-2Q)

Grade C-$1.53-19.6% Next Q

Q3 (-1Q)

Grade D$1.23-2.4% Next Q

Current

Grade D$1.20-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SLBT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SLBT currently carries a cautious 45/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.86) and Max Pain ($1.26) forces dealer call-delta covering toward $15.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SLBT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SLBT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SLBT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$18.4M (0.5% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	0%	$0	$0	15%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SLBT)

✓Walkthrough of SLBT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SLBT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -85.90%▲ RESISTANCE BREAKOUT

2026-11-02O $1.21H $1.21L $1.17C $1.20VOL 24.6K

RES: $1.12SUP: $0.90SMA50: $1.86SMA200: $6.04

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SLBT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SLBT Butterfly Map → + Track SLBT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SLBT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SLBT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SLBT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SLBT)

Health Care Rank #407 of 1016 ⚔️ AURA vs SLBT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SLBT vs. AURA, CADL, DBVT, IAM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SL Science Holding Limited (SLBT) ranks #407 by composite RQD confidence (45/100, grade D) and #409 by equity capitalization ($656.1M). Within this direct 5-issuer industry benchmark cohort, SLBT leads on earnings valuation at N/A trailing P/E, while AURA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with SLBT at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SLBT ACTIVE SL Science Holding Limited	D	45/100	—	—	—	+2.56%	$656.1M	Benchmark Subject
AURA Aura Biosciences Inc.	E	31/100	—	—	-35.0%	-2.46%	$652.8M	/aura-vs-slbt →
CADL Candel Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.70%	$661.9M	/cadl-vs-slbt →
DBVT DBV Technologies S.A.	E	23/100	—	—	-35.0%	-7.77%	$647.0M	/dbvt-vs-slbt →
IAM Iambic Therapeutics Inc.	D	49/100	—	—	—	-5.95%	$676.9M	/iam-vs-slbt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002070534

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SL Science Holding Limited (SLBT) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, SLBT closed FY2025 with $11.8K in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$11.8K	—

3. SLBT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SLBT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SLBT compare to AURA and CADL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SLBT?

Where is SLBT trading relative to its 50-day, 200-day, and 52-week technical levels?

SLBT last traded at $1.20 (+2.56% on volume of 26,623 shares), positioning the stock -35.48% below its 50-day simple moving average ($1.86) and -80.13% below its 200-day simple moving average ($6.04). Across its 52-week range of $1.02 to $14.50, SLBT sits at the 1.3% percentile with a 14-day RSI of 28.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.05 to $1.35).

SLBT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is SL Science Holding Limited (SLBT)?

In FY 2025 (10-K), SLBT converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $18.4M in free cash flow (0.5% FCF margin).

Direct Sub-Reports: SLBT RQD Cockpit SLBT 12M Forecast SLBT Earnings & Move SLBT Dividends & DRIP SLBT Insiders & 13F SLBT Whale Options SLBT Profit Sankey SLBT News & Why

ROARABLE RATING BRIEF • RQD 45/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SLBT — SL Science Holding Limited: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:19Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SLBT scores 45 out of 100, earning a "D" grade and the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, ROIC is 0% and FCF yield is 0%. For a prospective investor, this indicates the company is not currently generating returns on invested capital or free cash flow per the source data, so the stock's value case cannot rest on current cash generation.
Whale 13F Flow: 3 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning, and it is the weakest pillar. The low score suggests limited supportive institutional positioning in the source data.
Insider Conviction: 9 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The below-midpoint score indicates insider signals are not strongly supportive.
Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, beta is 1.0 and the pillar reflects sector sensitivity. A neutral beta means the stock moves roughly with the market, offering no defensive cushion or special macro tailwind.
Forensic Balance Sheet: 13 / 20. Per the Roarable RQD rating, the Altman Z is 2.5, the Piotroski F is 6/9, and Debt/Equity is 0.5. This is the strongest pillar, indicating the balance sheet is the most constructive element in the source data, though it does not offset weak cash generation.

Investor implication: the combined score and verdict point to elevated risk. Upside would require a turnaround in cash generation and institutional or insider conviction, neither of which the source data demonstrates. Valuation tradeoffs cannot be meaningfully assessed because P/E and EV/EBITDA are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	N/A	N/A

Per the SEC financials, FY 2025 reports zero revenue, operating income, and net income, with EPS, FCF, cash, and debt not reported. Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with Debt/Equity at 0.5. The forensic balance sheet metrics are the only reported strength in the source data, while profitability and returns are absent.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals. Upstream and downstream dependencies cannot be identified from source data. Sector classification is Health Care and industry is Biotechnology: Biological Products (No Diagnostic Substances); no sector correlation data is provided. Second-order bottlenecks cannot be assessed from source data.

Open Questions

What products or therapies does SL Science Holding Limited develop or sell, and is there any revenue-generating activity behind the zero reported figures?
Why are FY 2025 revenue, operating income, net income, cash, and debt all reported as zero or N/A, and what does the company's cash runway look like?
What explains the stock's decline from a 52-week high of $14.5 to a price of $1.17, and is there any reported catalyst behind it?
What is the status of institutional and insider holdings, given that the holders and analyst data are absent?
Which supply-chain relationships, partners, or regulatory milestones bear on the company's prospects, given no butterfly links are recorded?

SLBT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for SL Science Holding Limited (SLBT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SLBT Debate Forum (3) ↓

🟢 CATALYST Yahoo • 7d ago

SL Science Holding Limited Reports First Half 2026 Financial Results

Net revenue rose 23% to $1.39 million with gross margin expanding to 40.2%, driven by B2B distribution growth and reduction in purchase costs compared with last period due to establishment of stable relationships with su

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 7d ago

SL Science Holding H1 Sales $1.387M Up From $1.129M YoY

SL Science Holding (NASDAQ:SLBT) reported $1.387 million in sales this quarter. This is a 22.85 percent increase over sales of $1.129 million the same period last year.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 39d ago

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI, Taiwan, Sept. 24, 2026 (G

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 67d ago

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapie

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 76d ago

SL Science Holding (SLBT) Stock May Be Fully Priced Even After A 74% Fall

SL Science Holding has experienced a steep share price decline so far this year, while current valuation checks suggest the stock does not screen as a clear bargain. Year to date the share price is down 73.9%, which indi

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 83d ago

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 108d ago

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (γδ) T cells in eliminating glioblastoma in preclinical studies. TAIPEI, TAIWAN, July 17, 2026 (GLO

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 115d ago

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SLBT Bull vs. Bear Conversation Board — What's Your Call at $1.20?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SLBT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.03 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SLBT (D • RQD 45/100) a Buy at $1.17?

Welcome to the SLBT (SL Science Holding Limited) Roar Pit. Current RQD Composite is 45/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.97 (-17.1%)

Spot @ $1.17

Pump the brakes on SLBT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SLBT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless SL Science Holding Limited expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.40 (+19.7%)

Spot @ $1.17

SLBT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SLBT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $1.17 (52-wk range $1.02 - $14.50), any beat on forward guidance forces shorts and underweight funds to chase.